SUBSCRIBE
SUBSCRIBE
News   Drug Development

MethylGene Selects Histone Deacetylase Antifungal Clinical Candidate

May 17, 2007 | 
1 min read
MONTREAL, QUEBEC -- (MARKET WIRE) -- May 17, 2007 -- MethylGene Inc. (TSX: MYG), today announced the selection of MGCD290 as the clinical candidate emanating from its histone deacetylase (HDAC) antifungal program.
Preclinical
MORE ON THIS TOPIC
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie
illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
 · 
3 min read
 · 
Annalee Armstrong
3d human colon cross section with waste in the intestine isolated on green background. check colon health, constipation concept, 3d illustration render
Vaccines
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
February 17, 2026
 · 
3 min read
 · 
Dan Samorodnitsky